PIPRA Company Market Research Report

Company Overview

• Company Name: PIPRA AG

• Mission: To reduce the incidence of delirium through preventive measures enhanced by innovative AI-driven solutions.

• Founded: 2019

• Founders:

• John Klepper: CEO and Co-founder, a serial entrepreneur with extensive experience in technology and business.

• Nayeli Schmutz, Med. Pract.: CMO and Co-founder, a medical professional specializing in anesthesiology and intensive care.

• Benjamin Dodsworth, PhD: CTO and Co-founder, life scientist with a focus on brain health and AI.

• Key People:

• John Klepper: Chief Executive Officer.

• Nayeli Schmutz, Med. Pract.: Chief Medical Officer.

• Benjamin Dodsworth, PhD: Chief Technical/Scientific Officer.

• Mary-Anne Kedda, PhD: Head of Research & Medical/Grant Writer.

• Fabian Gautschi: Head of Product.

• Beatriz F. Cuadrado, PhD: Head of Sales.

• Christophe Loeffler: Chief Financial Officer.

• Headquarters: Zurich, Switzerland

• Number of Employees: 2-10 employees

• Revenue: No information is available

• Known For: Developing AI-based pre-surgical tools for assessing the risk of Postoperative Delirium (POD) and cognitive impairment following surgery.

Products

Delirium Management Program

• Description: A comprehensive program integrating digital technology and AI to manage and reduce the occurrence of Postoperative Delirium (POD) in healthcare settings.

• Key Features:

• Delirium Risk Assessment & Prevention Software: Fully automated and secure, embedded into clinical workflows.

• Automated & Customizable Reports: Provides updates on screening, prevention compliance, and delirium alerts.

• E-Learning: Video-based training for care staff.

• Apps & Materials: Access to delirium-related apps and educational materials for healthcare stakeholders.

Recent Developments

• New Products Launched:

• Development of an AI-based tool for pre-surgical risk assessment to prevent POD and POCD.

• New Features:

• PIPRA’s solution reduces delirium incidence by 29%, hospital stay length by 1.36 days, and nursing hours by 19.3 hours per medium-risk patient.

• New Partnerships:

• Collaboration with Medtech Europe for research on delirium prevention.

• Introduction of Delirium Hub, an online platform for global education and support in delirium management.

Achievements and Recognition

• PIPRA has been involved in significant research publications, notably in JAMA and Age and Ageing, highlighting the impact of its delirium management tools.

• Recognition at various events like Digital Health Day and Basel Healthtech’s Start-up Showcase.

• Awards include CSS Innovation in Health Award and Vadian Innovation Prize.

• Holds Innosuisse Certification as of February 2024.

Solution Impact

• PIPRA’s delirium management program has shown cost-effectiveness by saving 12.5M CHF annually and reducing the average length of stay by 1.36 days.

• The AI-powered solution has proven superior in predicting postoperative delirium risk compared to standard care.

Future Outlook

• PIPRA continues to seek partnerships and collaborations globally to advance its research and clinical application in delirium prediction, diagnosis, treatment, and prevention.

This detailed report is designed to capture various information about PIPRA AG using available data, emphasizing its mission, innovative offerings, and recent advancements in the field of medical technology concerning delirium management.